Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development Strengthened financial profile with continued royalty revenue growth Ended first quarter 2026 with approximately $7.3 million in cash while continuing evaluation of strategic alternatives to maximize shareholder value FRAMINGHAM, MA / ACCESS Newswire / May 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform. Recent Highlights Generated robust translational data supporting the DNase I platform across multiple oncology settings Completed process improvement and analytical development activities supporting future clinical manufacturing readiness Established translational and biomarker insights intended to help inform and de-risk future clinical trial design Collaboration partner received approval from Israeli Ministry of Health to conduct investigator-initiated exploratory study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma "We entered 2026 with a clear focus on advancing the translational, manufacturing and clinical foundation of our DNase I platform while maintaining financial discipline," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.